[ET Net News Agency, 15 January 2018] 3SBio Inc. (01530) said it entered into an
exclusive licensing agreement with Toray Industries, Inc. on certain oral disintegration
tablet formulation of antipruritic drug TRK-820 (also known as "REMITCH") that is
developed and manufactured by Toray.
Toray agreed to grant 3SBio the exclusive right to develop and commercialize the product
in the People's Republic of China (not including Hong Kong, Macau and Taiwan). 3SBio
agreed to pay initial payment and milestone payments to Toray.
The soft capsule dosage-form of the TRK-820 has been sold as in Japan since 2009 to
treat hemodialysisrelated uremic pruritus (used only when sufficient efficacy is not
obtained with the existing therapies or treatments). Oral disintegration tablet was
approved and launched in Japan in 2017. (HL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01530 3SBIO
Nominal 
6.050 +0.220 (+3.774%) Others
15/01/2018 16:38
3SBio granted right to develop antipruritic drug in PRC
| Remark: | Real time quote last updated: 25/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |